Maharashtra deputy CM Shinde directs instant panchnama of crop damage
Eknath Shinde
said on Saturday in Thane that district collectors have been issued instructions to immediately initiate panchnama of fields in regions where there was heavy rainfall and incidents of crop damage were reported.
Shinde was responding to local media queries about the losses suffered by farmers in regions where there was heavy rainfall over the last few days.
"This govt is sensitive towards the farmers. We have instructed district collectors to launch instant panchnamas in affected areas where crops are likely to have been hit by heavy rainfall," Shinde said. He announced that the urban development department will allocate Rs 5 crore to the Thane municipal corporation's health department for its cervical cancer screening initiative started under the 'Deputy CM Healthy Women Campaign'.
Modern diagnostic tools such as ultrasound machines and a mammography van have been deployed that will screen the health of over five lakh women free of cost over the next three months. The focus will be on the early detection of cervical cancer, diabetes, haemoglobin tests, HPV vaccination for girls aged 9–14, and awareness of healthy lifestyles, among others, Shinde said.
You Can Also Check:
Mumbai AQI
|
Weather in Mumbai
|
Bank Holidays in Mumbai
|
Public Holidays in Mumbai
Addressing the gathering, Shinde said, "Cervical cancer is the second most common cancer in women globally and can be treated effectively if diagnosed early. Women often neglect their own health while caring for their families. I urge all my laadki bahins (women) to participate in this health camp and prioritise their well-being," he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
2 hours ago
- New Indian Express
Karnataka government aids a grieving wife to bring back mortal remains of her husband from Guyana
MADIKERI: The Karnataka government has come to the aid of a bereaved wife who lost her husband to illness in Guyana of South America. The State will pay Rs 3.6 lakh to bring the victim's mortal remains to India. The deceased PB Girish was a resident of Madenadu village in Kodagu. He was working as a staff nurse at a hospital in Guyana of South America. He fell ill and was under medical assistance from July 3. He is said to have succumbed to a heart attack at a hospital in Guyana on July 14. However, the family learnt that it would cost them about Rs 12 lakh to bring the mortal remains of Girish back to India. Following it, Girish's wife Janaki met CM Siddaramaiah and requested help from the state to pay the amount to bring back the mortal remains. The victim's kin had also approached Virajpet MLA AS Ponnanna seeking help. Following these developments, the Under Secretary to the Government of the State Protocol, Foreign Cell Personnel and Administrative Reforms Department, has directed the Commissioner of Karnataka Bhavan in New Delhi to pay Rs 3.6 lakh to bring Girish's mortal remains back to his homeland. The rest of the amount will be borne by the Sheriff General Hospital at Guyana, where Girish served as the staff nurse. The Indian Embassy at Guyana will initiate steps to bring the body back to the country at the earliest.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Natco Pharma to acquire 35.75% stake in Adcock Ingram for ₹2,000 cr
The proposed Rs 2,000 crore deal will give Natco Pharma a strategic foothold in South Africa, with transaction completion expected within four months subject to approvals Sanket Koul New Delhi In a bid to enter the African market, Natco Pharma on Wednesday announced that it has submitted a firm intention for a ZAR 4 billion (Rs 2,000 crore) cash offer to acquire a minority stake in South Africa-based drugmaker Adcock Ingram Holdings (AIHL). If approved, the Hyderabad-based company will hold a 35.75 per cent stake in Adcock Ingram by offering ZAR 75.00 ($4.271) per share to minority stakeholders. The deal gives Natco a gateway into South Africa, with AIHL holding a 10 per cent share of the private pharmaceutical market in the country. It is also the largest supplier of hospital and critical care products in South Africa. This transaction would consolidate Natco's existing 0.80 per cent stake, making it the second-largest shareholder in AIHL, behind the Bidvest Group, which holds the remaining 64.25 per cent. 'Post-transaction, Natco will consolidate 35.75 per cent of AIHL's net profits in Natco's financial results in accordance with its shareholding,' the company said in a regulatory filing. If the deal proceeds, Adcock Ingram will be delisted from the Johannesburg Stock Exchange (JSE) and will continue to operate as a private South African business. Rajeev Nannapaneni, chief executive officer and vice-chairman of Natco Pharma, said the proposed acquisition would help the company tap into new revenue streams and expand its presence in one of the largest and fastest-growing emerging markets. In return, AIHL is expected to leverage Natco's research and development capabilities, regulatory expertise, and global marketing network to support local leadership and expansion into new markets. 'AIHL will benefit from a partnership with a research-focused, innovative, and vertically integrated pharmaceutical company, and over time, South Africans will be beneficiaries of wider access to affordable medicines,' said Andrew Hall, chief executive officer, AIHL. Valued at an estimated ZAR 11 billion ($632 million), AIHL generated revenues of ZAR 9.6 billion ($536 million) for the financial year ending June 2024. Founded in 1890, the company operates across four segments—prescription, consumer, over-the-counter (OTC), and hospitals. It has a diverse product portfolio ranging from generic and branded formulations to critical-care hospital products, as well as consumer and home-care products. The announcement was made after market hours. On Wednesday, Natco Pharma's shares rose by 2.01 per cent, ending the day's trade at Rs 1,034.75 apiece on the Bombay Stock Exchange (BSE).
Hans India
4 hours ago
- Hans India
Dr. Reddy's Laboratories' net profit slumps 11 pc to Rs 14,09 crore sequentially in Q1
Mumbai: Dr. Reddy's Laboratories' net profit stood at Rs 1,409.6 crore in the first quarter of the current fiscal (Q1 FY26), down 11 per cent sequentially, the company said in an exchange filing on Wednesday. The company had reported a consolidated profit of Rs 1,587.3 crore in the preceding quarter (Q4 FY25). However, the profit of the Hyderabad-based firm saw a marginal jump of over a per cent on year-on-year (YoY) from Rs 1,392 crore in the same quarter a year ago, according to the filing. Meanwhile, Dr. Reddy's Labs revenue stood at Rs 8,545.2 crore in the quarter under review, up around Rs 40 crore sequentially from Rs 8,506 crore, and Rs 872.5 crore year-on-year (YoY) from Rs 7,672.7 crore. The pharmaceutical company saw a jump of Rs 153 crore in its total operating expenses this quarter QoQ, leading to a decline in its net profit. The company reported total operating expenses of Rs 3,115.2 crore in Q1 FY26 against Rs 2,961.6 crore in Q4 FY25. "We delivered double-digit growth this quarter over the same period last year, reflecting our strength in branded markets and positive momentum in the Nicotine Replacement Therapy portfolio. The pricing pressure on Lenalidomide is expected to intensify in the U.S. generics market," said GV Prasad, Co-Chairman and MD. "We remain focused on strengthening our base business by delivery of our pipeline assets, improving overall productivity and business development," Prasad added. Meanwhile, the company has expanded partnership with Alvotech to co-develop, manufacture and co-commercialise pembrolizumab, a biosimilar candidate, this quarter, as per the filing. It has also launched Sensimune in India, an immunotherapy product for house dust mite-induced allergies. The shares of the company closed in positive territory on Wednesday. The stock settled at Rs 1,248.0, up 0.65 per cent. Dr. Reddy's Laboratories is a global pharmaceutical company headquartered in Hyderabad.
